On the morning of 27 August 2018, Beroni Biotechnology Co., Ltd, the Chinese subsidiary of Beroni Group Ltd signed a long-term product sales agreement and a short-term service agreement with Beijing Youlian Ear, Nose and Throat Hospital (“Beijing Youlian”), a subsidiary of HNA Group to share existing products and to provide enhanced services.
Beijing Youlian is a specialized hospital integrating medical treatment, teaching, scientific research, disease prevention and healthcare. The hospital consists of departments such as otolaryngology head and neck surgery, ophthalmology, stomatology, plastic surgery, etc. and covers an area of 12,000 square meters. To date, it can provide 65 hospital beds. Beijing Youlian is the first hospital owned by Beijing Medical Center jointly established by Capital Medical University and HNA Unicare, and it is the first specialized hospital of HNA Group.
HNA Group is a Chinese conglomerate headquartered in Haikou, Hainan with diversified business interests across aviation, tourism, logistics and financial services. In the future, Beroni Group will take advantage of HNA Group’s resource platform to effectively promote its existing products including the medical, beauty and health items. This will help expand Beroni’s popular products to the broad Chinese market, and enhance the reputation of the “Beroni” brand. In addition, Beijing Youlian will engage Beroni to arrange for tumor whole genome genetic testing, anti-aging beauty gene detection, and human whole genome sequencing. The cooperation lays a good foundation for Beroni Group to market its products and services in the Greater China Region.
Beroni Group’s Executive Chairman, Mr Jacky Zhang and Mr. Weiguo Zhou, Dean of Beijing Youlian ENT Hospital talked about the cancer treatment at home and abroad. Both sides agreed that actively learning the advanced immunotherapy technologies of various countries in the world would create a new hope for cancer treatment.
At the signing ceremony, Mr. Jacky Zhang said: “Working with Beijing Youlian is yet another example of how Beroni can leverage its rapidly advancing networks in life science, environmental science, precision medicine, stem cell anti-cancer and anti-aging treatments. Partnership with Beijing Youlian is first of its kind for Beroni. I hope Beroni can work closely with Beijing Youlian to deliver results satisfactory to both parties and more importantly the people we cared for. A successful partnership will also see Beroni replicating this model in other parts of China and Japan.”
This cooperation is a good beginning for the relationship between Beroni Group and Beijing Youlian. The two parties will work together to jointly promote the development and transformation of the health industry in China.
